Professional medical society
Appears in 4 stories · Last updated Nov 8, 2026
Hosted presentation of JNJ-6143 Phase 1 data at 2026 Congress
Johnson & Johnson's experimental prostate cancer drug JNJ-6143 shrank tumors in 12 of 16 patients with measurable disease in a Phase 1 trial. The results were presented October 24 at the European Society for Medical Oncology Congress, and J&J's press release followed a day later.
Updated 3 days ago
Host of the 2026 congress where the data was presented
Innovent Biologics presented the first clinical data for IBI3001, an EGFR/B7H3 bispecific antibody-drug conjugate (ADC, a targeted drug carrying a chemotherapy payload), at the 2026 European Society for Medical Oncology (ESMO) congress. Of 57 patients who received the drug, 78.9% had two or more prior treatment lines. Among 53 patients evaluable for response, 30.2% responded and 88.7% had disease control.
Updated Oct 26
Host of the 2026 congress where IBI354 data was presented
Innovent presented Phase 2 results at the European Society for Medical Oncology (ESMO) congress on October 24. The data show its experimental HER2-targeting antibody-drug conjugate (ADC), IBI354, plus pertuzumab produced a 95% confirmed response rate in patients with unresectable, locally advanced or metastatic HER2-positive breast cancer. That is 19 of 20 patients, and none developed interstitial lung disease (ILD), a lung inflammation that is a known risk with trastuzumab deruxtecan (Enhertu).
Hosted the ESMO Congress 2026 where the substudy was presented
Apalutamide taken for six months before and after prostate cancer surgery cut the risk of recurrence or death by 62% compared with surgery alone in a 408-patient substudy of the PROTEUS trial. Johnson & Johnson reported the results on Oct. 24, 2026; they were presented at the ESMO Congress in Madrid and accepted for publication by European Urology.
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
